Lakewood-Amedex Biotherapeutics Inc. (LABT)

Lakewood-Amedex Biotherapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

LABT Financials Overview

Financials in millions usd. Fiscal year is January - December.

Millions usd. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Income	-3.92	-4.03	-8.64
Net Income	-3.96	-4.86	-8.28

Fiscal Year	Current	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	0.66	0.68	6.39
Total Debt	1.69	0.27	0.58
Net Cash (Debt)	-1.03	0.41	5.81
Net Cash Growth	-	-92.97%	-

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-2.26	-5.72	-6.82
Capital Expenditures	0	-0	-
Free Cash Flow	-2.26	-5.73	-6.82
Free Cash Flow Growth	-	-	-